Skip to content

Study · Not a test of the peptide alone · 2024

5 results

Real world study of GLP-1 receptor agonists in overweight or obese type 2 diabetes by using repeated measurement analysis of variance.

Yang W, Zhou X, Miao Y, Wang L, Zhao Y, Ke T, Ban L

Medicine1 Aug 2024

PMID39121301 (opens in a new tab)PMCIDPMC11315522 (opens in a new tab)DOI10.1097/md.0000000000038879 (opens in a new tab)PepBankPUB-39121301
Download PDFPubMedAsk about this study
Jump to 5 results

Summary

To investigate the safety and efficacy of long-acting glucagon like peptide-1 receptor agonists in overweight or obese patients with type 2 diabetes. Overweight or obese patients with type 2 diabetes from July 2021 to June 2022 were randomly divided into control group (metformin) and experimental group (metformin + dulaglitide or semaglutide). Repeated measures analysis of variance was used to compare Hemoglobin A1c, fasting plasma glucose and body mass index (BMI) of patients before treatment, 6 months and 12 months after treatment. The adverse reactions of patients before treatment and 12 months after treatment were analyzed. The time effect of Hemoglobin A1c, fasting plasma glucose and BMI in the control group (n = 35) and the experimental group (n = 32) were statistically significant (P < .001), and the intergroup effect of BMI was statistically significant (P < .05). The interaction effect of BMI was statistically significant (P < .001). The BMI level of the experimental group was lower than that of the control group at 6 and 12 months after treatment (P < .001). There was no significant difference in the incidence of adverse reactions between the 2 groups (P > .05). Long-acting glucagon like peptide-1 receptor agonists, such as dulaglitide and semaglutide, not only reduce glycosylated hemoglobin levels, but also significantly improve BMI in overweight or obese patients with type 2 diabetes.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

  1. 01HumanNot a test of Semaglutide aloneRandomized controlled trialEfficacy outcome

    In overweight or obese adults with type 2 diabetes, HbA1c changed significantly over time (before treatment, 6 and 12 months) in both the metformin group and the metformin plus dulaglutide or semaglutide group; the direction is not stated.

    In plain wordsIn adults with type 2 diabetes, HbA1c changed over 12 months in both groups; the abstract does not state the direction.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedHbA1c time effect
    Study

    n = 67

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    The time effect of Hemoglobin A1c, fasting plasma glucose and BMI in the control group (n = 35) and the experimental group (n = 32) were statistically significant (P < .001), and the intergroup effect of BMI was statistically significant (P < .05).
    1 context sentence
    Summary · context
    Overweight or obese patients with type 2 diabetes from July 2021 to June 2022 were randomly divided into control group (metformin) and experimental group (metformin + dulaglitide or semaglutide).

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  2. 02HumanNot a test of Semaglutide aloneRandomized controlled trialEfficacy outcome

    In overweight or obese adults with type 2 diabetes, fasting plasma glucose changed significantly over time in both the metformin group and the metformin plus dulaglutide or semaglutide group; the direction is not stated.

    In plain wordsIn adults with type 2 diabetes, fasting blood glucose changed over 12 months in both groups; the abstract does not state the direction.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedFasting plasma glucose time effect
    Study

    n = 67

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    The time effect of Hemoglobin A1c, fasting plasma glucose and BMI in the control group (n = 35) and the experimental group (n = 32) were statistically significant (P < .001), and the intergroup effect of BMI was statistically significant (P < .05).
    1 context sentence
    Summary · context
    Overweight or obese patients with type 2 diabetes from July 2021 to June 2022 were randomly divided into control group (metformin) and experimental group (metformin + dulaglitide or semaglutide).

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  3. 03HumanNot a test of Semaglutide aloneRandomized controlled trialEfficacy outcome

    In overweight or obese adults with type 2 diabetes, BMI changed significantly over time in both the metformin group and the metformin plus dulaglutide or semaglutide group; the direction is not stated.

    In plain wordsIn adults with type 2 diabetes, BMI changed over 12 months in both groups; the abstract does not state the direction.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedBMI time effect
    Study

    n = 67

    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    The time effect of Hemoglobin A1c, fasting plasma glucose and BMI in the control group (n = 35) and the experimental group (n = 32) were statistically significant (P < .001), and the intergroup effect of BMI was statistically significant (P < .05).
    1 context sentence
    Summary · context
    Overweight or obese patients with type 2 diabetes from July 2021 to June 2022 were randomly divided into control group (metformin) and experimental group (metformin + dulaglitide or semaglutide).

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  4. 04HumanNot a test of Semaglutide aloneRandomized controlled trialEfficacy outcome

    In overweight or obese adults with type 2 diabetes, BMI was lower with metformin plus dulaglutide or semaglutide than with metformin alone at 6 and 12 months.

    In plain wordsIn adults with type 2 diabetes, adding dulaglutide or semaglutide to metformin gave lower BMI than metformin alone at 6 and 12 months.

    Peptide
    Semaglutide
    Outcome
    DecreaseBMI between groups at 6 and 12 months
    Study

    n = 67

    Comparator
    Metformin alone
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    The BMI level of the experimental group was lower than that of the control group at 6 and 12 months after treatment (P < .001).
    3 context sentences
    Summary · context
    the intergroup effect of BMI was statistically significant (P < .05)
    Summary · context
    The interaction effect of BMI was statistically significant (P < .001).
    Summary · context
    Overweight or obese patients with type 2 diabetes from July 2021 to June 2022 were randomly divided into control group (metformin) and experimental group (metformin + dulaglitide or semaglutide).

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  5. 05HumanNot a test of Semaglutide aloneRandomized controlled trialSafety outcome

    In overweight or obese adults with type 2 diabetes, the incidence of adverse reactions did not differ between metformin plus dulaglutide or semaglutide and metformin alone.

    In plain wordsIn adults with type 2 diabetes, side effects were not significantly more common when dulaglutide or semaglutide was added to metformin.

    Peptide
    Semaglutide
    Outcome
    No significant changeIncidence of adverse reactions
    Study

    n = 67

    Comparator
    Metformin alone
    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    There was no significant difference in the incidence of adverse reactions between the 2 groups (P > .05).
    1 context sentence
    Summary · context
    Overweight or obese patients with type 2 diabetes from July 2021 to June 2022 were randomly divided into control group (metformin) and experimental group (metformin + dulaglitide or semaglutide).

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.